Cost-effectiveness of lung MRI in lung cancer screening

Aberle DR, Adams AM, Berg CD et al (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395–409

Tanoue LT, Tanner NT, Gould MK, Silvestri GA (2015) Lung cancer screening. Am J Respir Crit Care Med 191:19–33

Bach PB, Mirkin JN, Oliver TK et al (2012) Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 307:2418–2429

Croswell JM, Baker SG, Marcus PM, Clapp JD, Kramer BS (2010) Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med 152(505-512):W176–W580

Pinsky PF (2014) Assessing the benefits and harms of low-dose computed tomography screening for lung cancer. Lung Cancer Manag 3:491–498

Biederer J, Ohno Y, Hatabu H et al (2017) Screening for lung cancer: does MRI have a role? Eur J Radiol 86:353–360

Meier-Schroers M, Homsi R, Skowasch D et al (2018) Lung cancer screening with MRI: results of the first screening round. J Cancer Res Clin Oncol 144:117–125

Sommer G, Tremper J, Koenigkam-Santos M et al (2014) Lung nodule detection in a high-risk population: comparison of magnetic resonance imaging and low-dose computed tomography. Eur J Radiol 83:600–605

Sonnenberg FA, Beck JR (1993) Markov models in medical decision making. Med Decis Making 13:322–338

Meza R, Hazelton WD, Colditz GA, Moolgavkar SH (2008) Analysis of lung cancer incidence in the Nurses’ Health and the Health Professionals’ Follow-Up Studies using a multistage carcinogenesis model. Cancer Causes Control 19:317–328

Ten Haaf K, van Rosmalen J, de Koning HJ (2015) Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials. Cancer Epidemiol Biomarkers Prev 24:154–161

Rosenberg MA, Feuer EJ, Yu B et al (2012) Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death. Risk Anal 32(Suppl 1):S25–S38

Ten Haaf K, Jeon J, Tammemagi MC et al (2017) Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study. PLoS Med 14:e1002277

Black WC, Gareen IF, Soneji SS et al (2014) Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med 371:1793–1802

Yabroff KR, Lamont EB, Mariotto A et al (2008) Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 100:630–641

Johnson KM, Fain SB, Schiebler ML, Nagle S (2013) Optimized 3D ultrashort echo time pulmonary MRI. Magn Reson Med 70:1241–1250

Burris NS, Johnson KM, Larson PE et al (2015) Detection of small pulmonary nodules with ultrashort echo time sequences in oncology patients by using a PET/MR system. Radiology 278:239–246

Menezes GL, Knuttel FM, Stehouwer BL, Pijnappel RM, van den Bosch M (2014) Magnetic resonance imaging in breast cancer: a literature review and future perspectives. World J Clin Oncol 5:61–70

Pisano ED, Gatsonis C, Hendrick E et al (2005) Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353:1773–1783

Pinsky PF, Gierada DS, Black W et al (2015) Performance of lung-rads in the national lung screening trial: a retrospective assessment. Ann Intern Med 162:485–491

Kinsinger LS, Anderson C, Kim J et al (2017) Implementation of lung cancer screening in the veterans health administration. JAMA Intern Med 177:399–406

van Klaveren RJ, Oudkerk M, Prokop M et al (2009) Management of lung nodules detected by volume ct scanning. N Engl J Med 361:2221–2229

De Koning H (2017) ES 02.01 The Dutch-Belgian Lung Cancer Screening Trial (NELSON). J Thorac Oncol 12:S1611

Pastorino U, Silva M, Sestini S et al (2019) Prolonged lung cancer screening reduced 10-year mortality in the MILD Trial: new confirmation of lung cancer screening efficacy. Ann Oncol 30:1162–1169

MacMahon H, Naidich DP, Goo JM et al (2017) Guidelines for management of incidental pulmonary nodules detected on ct images: from the Fleischner Society 2017. Radiology 284:228–243

Pyenson BS, Henschke CI, Yankelevitz DF, Yip R, Dec E (2014) Offering lung cancer screening to high-risk medicare beneficiaries saves lives and is cost-effective: an actuarial analysis. Am Health Drug Benefits 7:272–282